__NUXT_JSONP__("/drugs/Otlertuzumab", (function(a,b,c){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:"1372645-37-8",chebiId:b,chemicalFormula:b,definition:"A recombinant single-chain polypeptide engineered to exhibit the full binding and activity of an anti-CD37 monoclonal antibody with potential immunostimulatory and antineoplastic activities. Otlertuzumab binds to CD37 on B-cells, which may result in antibody-dependent cell-mediated cytotoxicity (ADCC) and apoptosis. CD37 is a transmembrane glycoprotein expressed at high-levels on B cells and to a lesser extent on T cells and myeloid cells. This agent may have a longer half-life in vivo than conventional monoclonal antibodies.",fdaUniiCode:"2MZ3L2664T",identifier:"C74006",preferredName:a,semanticType:"Pharmacologic Substance",subclassOf:["C2139"],synonyms:["Immunoglobulin, Anti-(Human CD Antigen CD37) (Synthetic Human-Mus Musculus Fragment TRU-016), Dimer","OTLERTUZUMAB",a,"TRU 016","TRU-016"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FOtlertuzumab",extension:".json",createdAt:c,updatedAt:c}}],fetch:{},mutations:void 0}}("Otlertuzumab","","2021-10-30T13:44:13.133Z")));